Cardiovascular disease prevention in patients with type 2 diabetes: the role of oral anti-diabetic agents
Open Access
- 1 December 2006
- journal article
- review article
- Published by SAGE Publications in Diabetes and Vascular Disease Research
- Vol. 3 (3), 147-158
- https://doi.org/10.3132/dvdr.2006.023
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trialThe Lancet, 2006
- Microalbuminuria as a marker of cardiovascular risk in patients with type 2 diabetesInternational Journal of Cardiology, 2006
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- Cardiovascular effects of the thiazolidinedionesDiabetes/Metabolism Research and Reviews, 2005
- Oxidative stress in atherogenesis and arterial thrombosis: the disconnect between cellular studies and clinical outcomesJournal of Thrombosis and Haemostasis, 2005
- Peroxisome proliferator-activated receptor-γ agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery diseaseAmerican Heart Journal, 2004
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complicationsJournal Of Hypertension, 1993
- Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patientsJournal Of Hypertension, 1993
- Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin ResistanceScience, 1993